Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Bernard Escudier,Robert J. Motzer,Padmanee Sharma,John Wagstaff,Elizabeth R. Plimack,Hans J. Hammers,Frede Donskov,Howard Gurney,Jeffrey A. Sosman,Pawel Zalewski,Ulrika Harmenberg,David F. McDermott,Toni K. Choueiri,Martin Eduardo Richardet,Yoshihiko Tomita,Alain Ravaud,Justin Doan,Huanyu Zhao,Helene Hardy,Saby George

Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

2016

4509Background: Immunotherapy response patterns differ from traditional therapies, and pts may benefit from treatment after initial RECIST progression (CCR 2009;15:7412–20). We investigated pts tre...

Keywords:

Nivolumab
Pathology
Renal cell carcinoma
Cancer research
Medicine
Checkmate
Oncology
Immunotherapy
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations